Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 100c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $82.00 +0.22%
EPS Growth %: +4.8%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: +4.8%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($1.39), $1.00 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $74.42 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
- Navan signs travel and expense deal with Viessmann Generations Group
- EU approves Arrowhead's plozasiran for rare triglyceride disorder
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
